UBS Group
IPSC icon

UBS Group’s Century Therapeutics IPSC Stock Holding History

UBS Group’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$569K Buy
232,409
+218,194
+1,535% +$498K ﹤0.01% 6149
2026
Q1 		$32.1K Sell
14,215
-200,286
-93% -$421K ﹤0.01% 7645
2025
Q4 		$213K Buy
214,501
+214,164
+63,550% +$131K ﹤0.01% 6542
2025
Q3 		$168 Sell
337
-27,689
-99% -$14.9K ﹤0.01% 9846
2025
Q2 		$15.7K Buy
28,026
+8,490
+43% +$4.55K ﹤0.01% 8597
2025
Q1 		$9.3K Sell
19,536
-17,560
-47% -$13.2K ﹤0.01% 8696
2024
Q4 		$37.5K Buy
37,096
+14,805
+66% +$20.2K ﹤0.01% 7484
2024
Q3 		$38.1K Buy
22,291
+8,196
+58% +$16.1K ﹤0.01% 6996
2024
Q2 		$35.9K Sell
14,095
-14,623
-51% -$46.2K ﹤0.01% 6943
2024
Q1 		$120K Buy
28,718
+3,125
+12% +$13.2K ﹤0.01% 6136
2023
Q4 		$85K Buy
25,593
+8,864
+53% +$16.1K ﹤0.01% 6271
2023
Q3 		$33.5K Buy
16,729
+2,715
+19% +$7.22K ﹤0.01% 6535
2023
Q2 		$44.3K Buy
14,014
+6,677
+91% +$21.5K ﹤0.01% 6542
2023
Q1 		$25.5K Buy
7,337
+1,884
+35% +$8.27K ﹤0.01% 6909
2022
Q4 		$28K Buy
+5,453
New +$51.5K ﹤0.01% 7313
2022
Q2 		– Sell
-32
Closed – – 10609
2022
Q1 		$0 Sell
32
-5,496
-99% -$72.8K ﹤0.01% 10551
2021
Q4 		$88K Buy
5,528
+5,046
+1,047% +$94.8K ﹤0.01% 6426
2021
Q3 		$12K Sell
482
-550
-53% -$14.9K ﹤0.01% 7765
2021
Q2 		$30K Buy
+1,032
New +$26.2K ﹤0.01% 6937

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

UBS Group's IPSC Position: Q2 2026 in Review

UBS Group increased its Century Therapeutics (IPSC) stake by 1,535% in Q2 2026, buying an estimated $498K and bringing the position to 232,409 shares worth $569K. The position accounts for ﹤0.01% of the portfolio, ranked #6149.

UBS Group first reported a position in IPSC in Q2 2021 and has held it in 19 quarters since. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • UBS Group held 232,409 shares of Century Therapeutics worth $569K as of Q2 2026.
  • UBS Group bought 218,194 Century Therapeutics shares in Q2 2026, an estimated $498K.
  • Century Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6149 holding.
  • UBS Group first reported a position in Century Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.